Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
26.33
USD
|
+3.25%
|
|
+0.30%
|
-21.96%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,890
|
2,600
|
2,680
|
1,772
|
1,567
|
1,225
|
-
|
-
|
Enterprise Value (EV)
1 |
2,118
|
2,962
|
3,144
|
2,357
|
1,811
|
1,309
|
1,106
|
1,004
|
P/E ratio
|
-168
x
|
18
x
|
65.4
x
|
114
x
|
37.9
x
|
21.5
x
|
13.5
x
|
9.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.49
x
|
6.05
x
|
4.95
x
|
2.66
x
|
2.32
x
|
1.77
x
|
1.6
x
|
1.47
x
|
EV / Revenue
|
5.03
x
|
6.89
x
|
5.81
x
|
3.53
x
|
2.68
x
|
1.89
x
|
1.45
x
|
1.2
x
|
EV / EBITDA
|
22.3
x
|
26.3
x
|
15.4
x
|
11.1
x
|
8.44
x
|
6.01
x
|
4.09
x
|
2.99
x
|
EV / FCF
|
30.5
x
|
40.6
x
|
39.4
x
|
20.5
x
|
13
x
|
7.24
x
|
5.31
x
|
3.87
x
|
FCF Yield
|
3.28%
|
2.47%
|
2.54%
|
4.89%
|
7.7%
|
13.8%
|
18.8%
|
25.9%
|
Price to Book
|
5.35
x
|
4.21
x
|
3.69
x
|
2.29
x
|
-
|
1.38
x
|
1.21
x
|
0.98
x
|
Nbr of stocks (in thousands)
|
41,731
|
43,444
|
44,544
|
45,882
|
46,438
|
46,523
|
-
|
-
|
Reference price
2 |
45.30
|
59.84
|
60.17
|
38.61
|
33.74
|
26.33
|
26.33
|
26.33
|
Announcement Date
|
20-02-20
|
21-02-25
|
22-02-24
|
23-02-28
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
421
|
429.6
|
541.5
|
666.8
|
675
|
693.6
|
764.4
|
833.3
|
EBITDA
1 |
94.86
|
112.6
|
204
|
212.7
|
214.5
|
217.7
|
270.5
|
336.1
|
EBIT
1 |
75.28
|
99.3
|
189.2
|
194.8
|
197.7
|
195.1
|
244.3
|
295.3
|
Operating Margin
|
17.88%
|
23.11%
|
34.94%
|
29.21%
|
29.28%
|
28.13%
|
31.96%
|
35.44%
|
Earnings before Tax (EBT)
1 |
-10.75
|
20.09
|
56.4
|
13.3
|
61.7
|
84.49
|
122.9
|
147
|
Net income
1 |
-11.02
|
145.5
|
41.98
|
15.91
|
41.96
|
60.38
|
91.2
|
114.8
|
Net margin
|
-2.62%
|
33.87%
|
7.75%
|
2.39%
|
6.22%
|
8.71%
|
11.93%
|
13.77%
|
EPS
2 |
-0.2700
|
3.330
|
0.9200
|
0.3400
|
0.8900
|
1.224
|
1.943
|
2.740
|
Free Cash Flow
1 |
69.5
|
73.03
|
79.85
|
115.2
|
139.5
|
180.9
|
208.1
|
259.6
|
FCF margin
|
16.51%
|
17%
|
14.75%
|
17.28%
|
20.67%
|
26.08%
|
27.23%
|
31.16%
|
FCF Conversion (EBITDA)
|
73.27%
|
64.87%
|
39.14%
|
54.15%
|
65.03%
|
83.07%
|
76.93%
|
77.26%
|
FCF Conversion (Net income)
|
-
|
50.18%
|
190.21%
|
724.11%
|
332.47%
|
299.55%
|
228.2%
|
226.21%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-20
|
21-02-25
|
22-02-24
|
23-02-28
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
127.7
|
159.2
|
158
|
169.4
|
167.5
|
172
|
160.3
|
169.5
|
163.9
|
181.2
|
166.3
|
173.4
|
172.3
|
182.8
|
189.1
|
EBITDA
1 |
48.14
|
69.34
|
53.83
|
44.92
|
55.23
|
58.77
|
41.9
|
54.26
|
52.94
|
65.39
|
46.2
|
52.81
|
51.28
|
60.75
|
61.8
|
EBIT
1 |
44.42
|
63.99
|
49.17
|
40.9
|
50.76
|
53.96
|
37.44
|
50.27
|
49.25
|
60.71
|
43.57
|
48.79
|
46.16
|
55.02
|
59.2
|
Operating Margin
|
34.78%
|
40.2%
|
31.12%
|
24.14%
|
30.31%
|
31.38%
|
23.35%
|
29.66%
|
30.04%
|
33.5%
|
26.2%
|
28.15%
|
26.79%
|
30.11%
|
31.3%
|
Earnings before Tax (EBT)
1 |
24.23
|
-6.197
|
7.294
|
22.01
|
2.069
|
-18.07
|
-26.47
|
37.85
|
16.6
|
33.72
|
20.47
|
23.06
|
20.25
|
20.72
|
27.5
|
Net income
1 |
17.66
|
-5.129
|
6.828
|
19.88
|
-0.693
|
-10.1
|
-19.54
|
25.76
|
10.86
|
24.87
|
13.69
|
16.15
|
14.16
|
16.38
|
20.62
|
Net margin
|
13.83%
|
-3.22%
|
4.32%
|
11.73%
|
-0.41%
|
-5.87%
|
-12.18%
|
15.2%
|
6.62%
|
13.72%
|
8.23%
|
9.31%
|
8.22%
|
8.96%
|
10.9%
|
EPS
2 |
0.3900
|
-0.1200
|
0.1500
|
0.4000
|
-0.0200
|
-0.2200
|
-0.4300
|
0.5100
|
0.2300
|
0.5000
|
0.2425
|
0.3100
|
0.2700
|
0.3650
|
0.3800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-03
|
22-02-24
|
22-05-04
|
22-08-03
|
22-11-03
|
23-02-28
|
23-05-03
|
23-08-02
|
23-11-02
|
24-02-29
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
228
|
363
|
464
|
585
|
244
|
83.9
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
119
|
221
|
Leverage (Debt/EBITDA)
|
2.402
x
|
3.222
x
|
2.273
x
|
2.751
x
|
1.137
x
|
0.3856
x
|
-
|
-
|
Free Cash Flow
1 |
69.5
|
73
|
79.9
|
115
|
139
|
181
|
208
|
260
|
ROE (net income / shareholders' equity)
|
20.9%
|
19.8%
|
20.2%
|
16%
|
-
|
11%
|
12.2%
|
16.6%
|
ROA (Net income/ Total Assets)
|
9.3%
|
9.17%
|
8.16%
|
6.43%
|
-
|
6.27%
|
7.71%
|
10.5%
|
Assets
1 |
-118.5
|
1,586
|
514.5
|
247.5
|
-
|
962.9
|
1,183
|
1,092
|
Book Value Per Share
2 |
8.470
|
14.20
|
16.30
|
16.90
|
-
|
19.00
|
21.80
|
26.90
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
10.2
|
37.8
|
45.9
|
30.1
|
15.2
|
17
|
22.8
|
25
|
Capex / Sales
|
2.41%
|
8.8%
|
8.47%
|
4.51%
|
2.25%
|
2.45%
|
2.99%
|
3%
|
Announcement Date
|
20-02-20
|
21-02-25
|
22-02-24
|
23-02-28
|
24-02-29
|
-
|
-
|
-
|
Last Close Price
26.33
USD Average target price
45.73
USD Spread / Average Target +73.67% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.96% | 1.22B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|